Multi-Omic Graph Diagnosis (MOGDx) : A data integration tool to perform classification tasks for heterogeneous diseases

Barry Ryan[®],^{1,*} Riccardo E. Marioni² and T. Ian Simpson¹

¹School of Informatics, University of Edinburgh, 10 Crichton Street, EH8 9AB, Edinburgh, UK and ²Centre for Genomic and Experimental Medicine, Institute of Genetics and Cancer , University of Edinburgh, Crewe Rd S, EH4 2XU, Edinburgh, UK

*Corresponding author. barry.ryan@ed.ac.uk

FOR PUBLISHER ONLY Received on Date Month Year; revised on Date Month Year; accepted on Date Month Year

Supplementary Figures

Supplementary Tables





Table 1. Model Parameters for Optimal Performance on Each Dataset

	Dataset Model	MME N	Iodality R	educed D	imensio	n	Shared Decoder Dimension	GCN Dimension
		mRNA miRNA DNAm CNV RPPA						
	BRCA	32	Х	32	16	16	32	32
	LGG	Х	Х	32	Х	Х	32	32
	KIPAN	Х	16	32	16	16	64	128
İ								

Best vs. Worst Modalities in BRCA





RPPA

DNAm

CNV

Fig. 2: Best and Worst Performing Modalities in Each Dataset

0.7



Fig. 3: Number of Samples per Modality in TCGA Datasets



Fig. 4: Percentage of Samples Included when Integrating Modalities



Fig. 5: BRCA Precision Recall Curve



Fig. 6: KIPAN Precision Recall Curve



Fig. 7: LGG Precision Recall Curve

Table 2. KIPAN: Optimal Modality Performance Summary. These accuracies are not weighted by the percentage of sample availability.

Project	Modality	Accuracy	F1
	CNV	0.76	0.74
	DNAm	0.95	0.93
	miRNA	0.95	0.94
	RPPA	0.98	0.98
	mRNA	0.92	0.9
	miRNA + DNAm	0.95	0.94
	miRNA + CNV	0.89	0.87
	mRNA + RPPA	0.95	0.94
	mRNA + DNAm	0.94	0.92
	mRNA + miRNA	0.93	0.92
	mRNA + CNV	0.9	0.88
	CNV + RPPA	0.91	0.89
	DNAm + CNV	0.88	0.86
	DNAm + RPPA	0.97	0.96
	miRNA + RPPA	0.97	0.96
KIPAN	miRNA + DNAm + RPPA	0.97	0.96
	mRNA + miRNA + CNV	0.93	0.92
	mRNA + miRNA + DNAm	0.94	0.93
	mRNA + CNV + RPPA	0.95	0.94
	mRNA + miRNA + RPPA	0.96	0.94
	DNAm + CNV + RPPA	0.95	0.94
	miRNA + CNV + RPPA	0.95	0.94
	mRNA + DNAm + CNV	0.94	0.92
	miRNA + DNAm + CNV	0.94	0.93
	mRNA + DNAm + RPPA	0.96	0.94
	mRNA + miRNA + CNV + RPPA	0.95	0.94
	mRNA + miRNA + DNAm + CNV	0.95	0.94
	mRNA + miRNA + DNAm + RPPA	0.96	0.95
	mRNA + DNAm + CNV + RPPA	0.96	0.94
	miRNA + DNAm + CNV + RPPA	0.96	0.95
	mRNA + miRNA + DNAm + CNV + RPPA	0.96	0.95

Project	Modality	Accuracy	F1
	CNV	0.66	0.64
	DNAm	0.90	0.88
	miRNA	0.68	0.65
	RPPA	0.65	0.64
	mRNA	0.69	0.66
	miRNA + DNAm	0.84	0.82
	miRNA + CNV	0.68	0.66
	mRNA + RPPA	0.72	0.69
	mRNA + DNAm	0.77	0.74
	mRNA + miRNA	0.7	0.68
	mRNA + CNV	0.72	0.69
	CNV + RPPA	0.73	0.7
	DNAm + CNV	0.85	0.82
	DNAm + RPPA	0.85	0.83
	miRNA + RPPA	0.67	0.65
LGG	miRNA + DNAm + RPPA	0.81	0.78
	mRNA + miRNA + CNV	0.72	0.7
	mRNA + miRNA + DNAm	0.75	0.72
	mRNA + CNV + RPPA	0.72	0.7
	mRNA + miRNA + RPPA	0.69	0.68
	DNAm + CNV + RPPA	0.82	0.79
	miRNA + CNV + RPPA	0.7	0.67
	mRNA + DNAm + CNV	0.8	0.77
	miRNA + DNAm + CNV	0.82	0.8
	mRNA + DNAm + RPPA	0.76	0.74
	mRNA + miRNA + CNV + RPPA	0.7	0.69
	mRNA + miRNA + DNAm + CNV	0.79	0.76
	mRNA + miRNA + DNAm + RPPA	0.78	0.75
	mRNA + DNAm + CNV + RPPA	0.79	0.76
	miRNA + DNAm + CNV + RPPA	0.79	0.76
	mRNA + miRNA + DNAm + CNV + RPPA	0.77	0.74

Project	Modality	Accuracy	F1
-	CNV	0.67	0.75
	DNAm	0.84	0.83
	miRNA	0.77	0.77
	RPPA	0.8	0.78
	mRNA	0.87	0.84
	miRNA + DNAm	0.82	0.81
	miRNA + CNV	0.78	0.77
	mRNA + RPPA	0.87	0.84
	mRNA + DNAm	0.88	0.86
	mRNA + miRNA	0.86	0.84
	mRNA + CNV	0.87	0.84
	CNV + RPPA	0.79	0.79
	DNAm + CNV	0.78	0.77
	DNAm + RPPA	0.83	0.82
	miRNA + RPPA	0.81	0.8
BRCA	miRNA + DNAm + RPPA	0.85	0.84
	mRNA + miRNA + CNV	0.87	0.85
	mRNA + miRNA + DNAm	0.88	0.86
	mRNA + CNV + RPPA	0.87	0.85
	mRNA + miRNA + RPPA	0.87	0.85
	DNAm + CNV + RPPA	0.84	0.82
	miRNA + CNV + RPPA	0.82	0.81
	mRNA + DNAm + CNV	0.88	0.86
	miRNA + DNAm + CNV	0.82	0.81
	mRNA + DNAm + RPPA	0.88	0.86
	mRNA + miRNA + CNV + RPPA	0.88	0.86
	mRNA + miRNA + DNAm + CNV	0.89	0.86
	mRNA + miRNA + DNAm + RPPA	0.89	0.87
	mRNA + DNAm + CNV + RPPA	0.89	0.87
	miRNA + DNAm + CNV + RPPA	0.85	0.83
	mRNA + miRNA + DNAm + CNV + RPPA	0.89	0.88

Table 4. BRCA Optimal Modality Performance. These accuracies are not weighted by the percentage of sample availability.

Table 5. BRCA Component Performance Fold Summary

			BRCA			
	PSN + MME		PSN	[MME	
	Accuracy	F1	Accuracy	F1	Accuracy	F1
Fold 1	0.903	0.884	0.871	0.839	0.857	0.833
Fold 2	0.894	0.870	0.88	0.85	0.829	0.795
Fold 3	0.871	0.857	0.899	0.885	0.834	0.816
Fold 4	0.889	0.869	0.907	0.886	0.843	0.82
Fold 5	0.907	0.890	0.861	0.83	0.843	0.821
	•					

Table 6. LGG Component Performance Fold Summary

LGG							
	PSN + MN		PSN		MMI	Ŧ	
	Accuracy	F1	Accuracy	F1	Accuracy	F1	
Fold 1	0.924	0.907	0.902	0.882	0.721	0.718	
Fold 2	0.913	0.895	0.924	0.909	0.685	0.662	
Fold 3	0.857	0.833	0.912	0.896	0.703	0.674	
Fold 4	0.934	0.92	0.879	0.856	0.648	0.672	
Fold 5	0.89	0.868	0.901	0.883	0.681	0.652	

 Table 7. KIPAN Component Performance Fold Summary

KIPAN								
	PSN + N	AME	PSN	[MME			
	Accuracy	F1	Accuracy	F1	Accuracy	F1		
Fold 1	0.955	0.945	0.966	0.956	0.972	0.962		
Fold 2	0.961	0.949	0.966	0.956	0.972	0.964		
Fold 3	0.961	0.951	0.978	0.971	0.961	0.954		
Fold 4	0.96	0.951	0.955	0.943	0.994	0.993		
Fold 5	0.955	0.942	0.966	0.955	0.977	0.971		

Dataset	Gene set	Term	Overlap	P-value	Adjusted P-value	Odds Ratio
		Estrogen Response Early	100/200	1.02445e-10	5.12225e-09	2.53256
	MSigDB Hallmark 2020	Epithelial Mesenchymal Transition	95/200	8.87321e-09	2.2183e-07	2.28852
DDCA		Myogenesis	91/200	2.20846e-07	3.68076e-06	2.10961
DIIOA		Axon guidance	103/182	1.7986e-15	5.71956e-13	3.3086
	KEGG 2021 Human	Proteoglycans in cancer	108/205	2.52725e-13	4.01832e-11	2.82438
		Pathways in cancer	227/531	9.28599e-13	7.96066e-11	1.90712
		Estrogen Response Early	106/200	1.19312e-11	5.96561e-10	2.63818
	MSigDB Hallmark 2020	Myogenesis	98/200	1.62511e-08	4.06277e-07	2.24345
KIDAN		Epithelial Mesenchymal Transition	93/200	7.80117e-07	9.75147e-06	2.02706
		Axon guidance	110/182	2.22215e-17	7.04421e-15	3.58235
	KEGG 2021 Human	Proteoglycans in cancer	113/205	7.72699e-14	1.22473e-11	2.87735
		Human papillomavirus infection	163/331	1.92237e-13	2.0313e-11	2.2797
		Estrogen Response Early	108/200	2.62026e-11	1.31013e-09	2.58899
	MSigDB Hallmark 2020	Epithelial Mesenchymal Transition	104/200	1.05084 e-09	2.62711e-08	2.38698
LCC		Apical Junction	98/200	1.47716e-07	2.46193e-06	2.11397
199		Axon guidance	113/182	1.28249e-17	4.0783e-15	3.62084
	KEGG 2021 Human	Focal adhesion	121/201	3.05032e-17	4.85001e-15	3.34571
		Proteoglycans in cancer	122/205	8.00606e-17	8.48642e-15	3.25124

Table 8. TCGA DNAm Over Representation Analysis Results

Table 9. TCGA mRNA Gene Set Enrichment Analysis Results

Dataset	Gene set	Term	ES	NES	NOM p-val	FDR q-val	Tag $\%$	Gene $\%$
		Pentose and glucuronate interconversions	-0.774355	-2.29015	0	0	10/16	9.58%
	KEGG 2021 Human	Cell cycle	0.573984	2.27577	0	0	48/108	16.26%
DDCA		Homologous recombination	-0.649829	-2.39384	0	0	13/25	14.04%
DRUA		G2-M Checkpoint	0.576235	2.46117	0	0	102/188	23.18%
	MSigDB Hallmark 2020	Androgen Response	-0.499048	-2.03848	0	0.00577345	37/68	25.03%
		Myc Targets V1	0.446703	1.88204	0	0.00801285	129/175	46.57%
		Nicotine addiction	0.80602	3.10307	0	0	15/18	11.28%
	KEGG 2021 Human	Systemic lupus erythematosus	-0.641083	-2.29704	0	0	35/52	20.32%
LCC		Type I diabetes mellitus	-0.737799	-2.2463	0	0	19/24	15.40%
LGG		G2-M Checkpoint	-0.672679	-2.6506	0	0	53/126	8.53%
	MSigDB Hallmark 2020	E2F Targets	-0.641025	-2.52297	0	0	66/137	15.34%
		Epithelial Mesenchymal Transition	-0.621457	-2.45649	0	0	94/144	23.64%
		Oxidative phosphorylation	0.623763	3.14138	0	0	87/112	24.92%
	KEGG 2021 Human	Pentose and glucuronate interconversions	-0.668482	-2.11695	0	0	11/24	10.08%
VIDAN		Intestinal immune network for IgA production	-0.624027	-2.15917	0	0	31/40	27.41%
KIFAN		Oxidative Phosphorylation	0.604961	3.25895	0	0	145/196	27.66%
	MSigDB Hallmark 2020	Allograft Rejection	-0.562653	-2.43625	0	0	118/178	27.41%
		Epithelial Mesenchymal Transition	-0.527188	-2.26799	0	0	111/166	30.88%